GSK to spend USD 100 M to boost its vaccine production Drug maker GlaxoSmithKline has announced to invest USD100 million in its vaccine production site in…
Apr 25 
Category: The Business Cocktail
Apr 18 
The Business Cocktail
Amgen reveals the price of EVENITY Amgen has set the price of its newly launched Osteoporosis drug Romosozumab (Evenity). Worth USD 21,900 per annum or USD…
Mar 28 
The Business Cocktail
Saama Technologies raises USD 40 Million to bolster AI Saama Technologies has got a hefty investment of USD 40million to accelerate its Artificial Intelligence and bolster…
Mar 14 
The Business Cocktail
BioNTech lines up USD 800 Million for fuelling mRNA R&D BioNTech is lining up a Nasdaq IPO that raises USD 800 million. The German mRNA specialist…
Feb 28 
The Business Cocktail
Cell Medica receives funds for its cell therapy A USD 8.7 million grant to Cell Medica has been given by Cancer Prevention and Research Institute of…
Feb 21 
The Business Cocktail
Peloton Therapeutics raises USD 150 Million for treating Advance Kidney Cancer Peloton Therapeutics has been in the process of developing small molecule drugs to treat Cancer, has…
Feb 14
The Business cocktail
Neurogene raises USD 68.5 Million for rare neurological diseases Neurogene netted USD 68.5 million to advance multiple gene therapy programs in its series A round. The…
Feb 7 
The Business Cocktail
Genentech remunerates Xencor USD 120 Million for global rights Genentech has remunerated USD 120 million upfront to have global rights to IL-15 cytokine therapeutics in preclinical development at…
Jan 31 
The Business Cocktail
Voyager clears Neurocrine agreement for Parkinson’s gene therapy Voyager Therapeutics is signing a collaboration agreement with Neurocrine Biosciences that will remunerate the Cambridge, Massachusetts-based biotech USD…
Jan 17 
The Business Cocktail
Anti-aging startup Juvenescence raises USD 46 Million Juvenescence has bagged the USD 46 million in series B financing. The investment tees the anti-ageing startup to progress the multi-asset…
